Patients with newly diagnosed DLBCL treated from January 1, 2006, through December 31, 2017, were identified. Electronic medical records were reviewed for documentation of American Society of Hematology Practice Improvement Module quality measures (eg, key pathologic features of DLBCL, lymphoma staging, and screening for hepatitis B virus [HBV] infection in patients receiving rituximab-based chemotherapy). We also reviewed assessment of prognosis by revised International Prognostic Index score, testing for hepatitis C virus, HBV, and HIV, chemotherapy education, and the addition of rituximab in the treatment regimen of CD20 DLBCL.
Following QII implementation, we saw improvements in most metrics, including reporting of key molecular features (fluorescence in situ hybridization for , , and , from 45.5% [75 of 165 patients] before QII to 91.7% [22 of 24 patients] after QII; <.001), screening for HBV (41.8% [69 of 165 patients] to 91.7% [22 of 24 patients]; <.001) and HIV infections (33.9% [56 of 165 patients] to 87.5% [21 of 24 patients]; <.0001), providing chemotherapy education (92.7% [153 of 165 patients] to 100%), and use of rituximab for CD20 DLBCL (83.6% [138 of 165 patients] to 100%; =.05). All patients had positron emission tomography-computed tomography for DLBCL staging, and there was significantly lower use of bone marrow biopsy (=.011).
Implementating a QII and employing standardized metrics can aid in improving quality of care for patients with newly diagnosed DLBCL and allow opportunities to build and ensure better adherence to evolving patient care guidelines.
© 2019 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc.